New HPV vaccine aims to block more cancer types in early trial
NCT ID NCT06688058
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new vaccine called V540D, designed to protect against more types of human papillomavirus (HPV) than the current Gardasil 9 vaccine. The study involves 72 healthy adults and will compare the safety and immune response of V540D to Gardasil 9. The main goal is to see if V540D is safe and well-tolerated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
V540D (experimental HPV vaccine with adjuvant)
What this could lead to
If successful, this could lead to a vaccine that protects against more types of HPV than current options, potentially preventing more HPV-related cancers.
What could go wrong
This is an early Phase 1 trial with only 72 healthy adults, focused on safety and immune response. It is too soon to know if the vaccine will work in the real world or be better than existing vaccines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Multispecialty Research, LLC ( Site 0003)
Kansas City, Missouri, 64114, United States
-
Alliance for Multispecialty Research, LLC ( Site 0004)
Knoxville, Tennessee, 37920, United States
-
Research Centers of America ( Hollywood ) ( Site 0001)
Hollywood, Florida, 33024, United States
-
Velocity Clinical Research, Savannah ( Site 0005)
Savannah, Georgia, 31406, United States